NEW YORK (GenomeWeb News) – Compugen will collaborate with Merck to develop a peptide that, based on recent in vitro and in vivo studies, potentially could be used in the treatment of inflammatory diseases and other indications.
The agreement covers additional research that Compugen will conduct on the CGEN-855 peptide, and gives Merck Serono an option to license it exclusively for worldwide development and commercialization.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.